Bristol-Myers Squibb Raises 2026 Revenue Guidance After Q3 Beat

Bristol-Myers Squibb raised its 2026 revenue guidance after third-quarter revenue and non-GAAP earnings per share exceeded estimates. Revenue reached $13.1 billion, up 7.2% from a year earlier.

Revenue topped estimates by $370 million. Non-GAAP earnings per share was $1.35, beating estimates by 13 cents.

Both results topped estimates in an earlier quarter preview, which projected revenue of $12.73 billion and earnings per share of $1.22.

For 2026, Bristol-Myers Squibb set a revenue range of $49.75 billion to $50.25 billion and a non-GAAP earnings-per-share range of $6.35 to $6.55. The EPS range includes a negative $0.60-per-share net impact from acquired in-process research and development charges and licensing income.